| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.03 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.088 | 0.03 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.03 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.03 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.03 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |